# The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP): The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP)

> **NCT07051174** · NA · COMPLETED · sponsor: **Sanoculis Ltd** · enrollment: 88 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DIAGNOSTIC_TEST:** MIMS

## Key facts

- **NCT ID:** NCT07051174
- **Lead sponsor:** Sanoculis Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-11
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-10-27
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07051174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07051174, "The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP): The Minimally Invasive Micro Sclerostomy (MIMS®) System is Intended for the Reduction of Elevated Intraocular Pressure (IOP)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07051174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*